Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$3.84 -3.3%	$4.22	$3.00 ▼ $25.45	$177.06M	0.47	528,540 shs	1.29 million shs
ICCC ImmuCell	$4.91 -1.2%	$5.14	$3.34 ▼ $6.09	$44.16M	0.23	21,567 shs	15,285 shs
VYGR Voyager Therapeutics	$3.19 -2.7%	$3.47	$2.75 ▼ $9.55	$176.52M	0.95	445,774 shs	284,151 shs
YMAB Y-mAbs Therapeutics	$3.64 -12.5%	$4.50	$3.42 ▼ $16.11	$164.81M	0.53	316,129 shs	238,734 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	-2.46%	-2.70%	-6.81%	+10.58%	-79.65%
ICCC ImmuCell	-5.15%	-3.12%	-8.13%	-1.58%	-5.69%
VYGR Voyager Therapeutics	-2.09%	+0.92%	+3.47%	-25.79%	-61.32%
YMAB Y-mAbs Therapeutics	+2.21%	+7.77%	-13.87%	-29.85%	-65.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	1.8165 of 5 stars	2.9	0.0	0.0	1.8	1.7	1.3
ICCC ImmuCell	0.2763 of 5 stars	0.0	3.0	0.0	2.6	0.0	0.0
VYGR Voyager Therapeutics	4.6536 of 5 stars	4.6	1.0	4.6	2.6	1.7	1.9
YMAB Y-mAbs Therapeutics	3.9652 of 5 stars	4.4	3.0	0.0	3.1	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	290.63% Upside
ICCC ImmuCell	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.11	Buy	$13.97	337.81% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$16.70	358.79% Upside

Current Analyst Ratings Breakdown

Latest ICCC, CRGX, VYGR, and YMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/21/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $12.00
3/13/2025	VYGR Voyager Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
3/13/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/12/2025	VYGR Voyager Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
3/12/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/12/2025	VYGR Voyager Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $18.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$9.84 per share	N/A
ICCC ImmuCell	$26.49M	1.67	N/A	N/A	$3.23 per share	1.52
VYGR Voyager Therapeutics	$66.96M	2.64	$2.26 per share	1.41	$5.37 per share	0.59
YMAB Y-mAbs Therapeutics	$87.69M	1.88	N/A	N/A	$2.32 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$98.15M	-$3.72	N/A	N/A	N/A	N/A	-38.16%	-33.94%	N/A
ICCC ImmuCell	-$5.78M	-$0.29	N/A	∞	N/A	-15.99%	-15.32%	-8.81%	5/14/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.49	N/A	N/A	15.80%	8.33%	6.15%	N/A
YMAB Y-mAbs Therapeutics	-$21.43M	-$0.67	N/A	N/A	N/A	-28.22%	-24.61%	-18.49%	N/A

Latest ICCC, CRGX, VYGR, and YMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ICCC ImmuCell	N/A	$0.16	N/A	$0.16	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million
3/4/2025	Q4 2024	YMAB Y-mAbs Therapeutics	-$0.13	-$0.15	-$0.02	-$0.15	$26.70 million	$26.50 million
2/25/2025	Q4 2024	ICCC ImmuCell	N/A	$0.06	N/A	$0.06	N/A	$7.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	18.94	18.95
ICCC ImmuCell	0.36	3.11	1.44
VYGR Voyager Therapeutics	N/A	8.45	8.45
YMAB Y-mAbs Therapeutics	N/A	3.92	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
ICCC ImmuCell	13.47%
VYGR Voyager Therapeutics	48.03%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	1.38%
ICCC ImmuCell	6.60%
VYGR Voyager Therapeutics	6.39%
YMAB Y-mAbs Therapeutics	22.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	46.11 million	45.39 million	N/A
ICCC ImmuCell	70	8.99 million	8.32 million	Not Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.15 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	34.71 million	Optionable

ICCC, CRGX, VYGR, and YMAB Headlines

Recent News About These Companies

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14 at 3:18 AM | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13 at 10:11 PM | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13 at 1:35 PM | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13 at 8:45 AM | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13 at 7:05 AM | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13 at 6:35 AM | globenewswire.com

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7, 2025 | globenewswire.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%

May 6, 2025 | aaii.com

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

May 6, 2025 | globenewswire.com

Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1%

May 5, 2025 | marketbeat.com

2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by Acorn Capital Advisors LLC

May 4, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 16.1% in April

May 4, 2025 | americanbankingnews.com

Caligan Partners LP Has $13.84 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 3, 2025 | marketbeat.com

Y-mAbs Therapeutics (YMAB) Projected to Post Earnings on Tuesday

May 1, 2025 | marketbeat.com

JPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 30, 2025 | marketbeat.com

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

April 29, 2025 | zacks.com

Boothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

April 29, 2025 | marketbeat.com

Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA

April 28, 2025 | markets.businessinsider.com

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures

April 27, 2025 | finance.yahoo.com

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

April 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC, CRGX, VYGR, and YMAB Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$3.84 -0.13 (-3.27%)

As of 04:00 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

ImmuCell NASDAQ:ICCC

$4.91 -0.06 (-1.21%)

As of 04:00 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Voyager Therapeutics NASDAQ:VYGR

$3.19 -0.09 (-2.74%)

As of 04:00 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$3.64 -0.52 (-12.50%)

As of 04:00 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time